Cellectis S.A.
- CLLS
- NASDAQ
- Biotechnology
- CAR-T/I-O Therapies
- Gene Editing (TALEN)
- Cancer Immunotherapy
$0.93
Today −11.01%Quote Oct 19, 2026, 08:00 PM UTC
−28.77%over the last month
Max drawdown −33.3%From 1-month high −33.3%3 months −60.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Cellectis
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
229
Market value
$93.2M
Quote Oct 19
Resistance
$0.95
3.0% above price
Price vs analyst targets
17 analysts
Lowest target
$1.30Highest target
$3.00
$1.30Highest target
$3.00
- Price $0.93
- Average target $2.15
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 132% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CLLSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free